In the sleep sector, efforts to connect what had been fragmented stages of diagnosis, treatment, and follow-up into a single continuum have become more prominent. Through Handok Sleep Science, Handok combined its experience in insomnia treatment with the digital therapeutic SleepQ and the smartphone-based sleep analysis technology ChronoTrack, aiming to expand a system in which clinicians can also reference data collected outside the clinic... Behind this shift is the reality that while the number of patients with sleep disorders is increasing, the time, specialized workforce, and accessibility needed for testing and consultation have not kept pace. As methods that allow testing to continue at home are introduced and academic leadership emphasizes accurate interpretation and standardized management of sleep disorders, sleep medicine is moving toward a stage that refines both lifestyle management and specialized diagnosis at the same time...

During the pandemic, Genencell’s COVID-19 treatment candidate, ‘ES16001,’ drew rapid attention with its natural-product-based approach, prompting several listed companies to invest. However, even after approval of the Phase 2 and 3 clinical trial plan—a key development milestone—the project failed to lead to commercialization. In the process, some companies suffered not only valuation losses but also broader management instability. The delisting decision against Sejong Medical and the case of Korea Pharma, which invested 3 billion won and later recognized losses, show how fragile the theme-driven capital formed during the infectious disease crisis ultimately was.

Sales channels are rapidly fragmenting, with Musinsa Beauty launching stores combined with Onnuri Pharmacy and Daiso opening cosmetics-focused specialty outlets. This reflects how cosmetics have evolved beyond simple beauty products into goods that consumers evaluate through consultation, ingredient knowledge, and price comparison, making traditional multi-brand shops insufficient to meet demand. Even department stores are now putting derma beauty specialty shops front and center, showing that function-focused consumption is reshaping the design of offline retail spaces. Ultimately, distributors have entered a stage where they differentiate store models for the same cosmetics depending on whom they are selling to, what evidence they provide, and at what price point.

Prevention and care targeting older adults are shifting from a peripheral issue to core health infrastructure. The development of GC녹십자’s [GC3114B], the approval of the [APEC Healthy Aging Action Plan 2026–2030], and the operation of community-level [long-term care home medical centers] all reflect the view that in a super-aged society, existing uniform services alone are no longer enough... The significance of this shift lies in redesigning the healthcare system away from simply covering treatment costs after illness occurs and toward prevention and home-visit care tailored to age and mobility. Going forward, vaccines, long-term care, and digital-based management are increasingly likely to be integrated into a health system customized for older adults rather than functioning separately.

In South Korea’s pharmaceutical and biotech sectors, clinical development is moving beyond simply speeding things up toward a more sophisticated stage of determining which patients to target and what evidence to build. GC Pharma’s decision to begin developing a highly immunogenic influenza vaccine for adults aged 65 and older also reflects growing demand to address the limitations of existing vaccines in the elderly... This shift is also evident in the regulatory environment. The United States has made clear that it will more strictly assess the reliability of data and the feasibility of inspections at overseas clinical trial sites, while major regulatory jurisdictions including South Korea are placing greater emphasis on detailed analytical and pharmacokinetic data while easing the burden of submitting Phase 3 clinical trial data for biosimilars...

The key issue in middle-aged women’s health is not simply aging, but that hormonal changes alter the direction of disease risk. While dyslipidemia places a heavier burden on men at younger ages, a trend has been confirmed in which LDL abnormalities increase around menopause, reversing in women’s 50s so that women surpass men. Postmenopausal bleeding is also treated not as a natural recovery phenomenon, but as a warning sign requiring separate evaluation. This shift matters because symptoms are often not obvious or can easily be mistaken for menopausal changes. In other words, the focus of care for middle-aged women is moving beyond merely relieving discomfort toward the early detection of cardiovascular disease and gynecologic cancer risks.

In the natural products and red ginseng market, products are rapidly expanding beyond pharmacies and specialty stores into everyday retail distribution and overseas wellness channels. Some companies, for example, have launched red ginseng products sold for 2,000 won at all Daiso stores through automation and bulk procurement, while another regional research institute has used cooperation with a Vatican monastery as a stepping stone to prepare for entry into the European beauty and wellness market. This trend is driven by the fact that growth potential is limited by domestic demand alone, while Korea’s enhanced image through K-content is serving as leverage for exports. The growing number of efforts focused more on securing market touchpoints than on immediate sales—such as on-site promotion in Los Angeles and export consultation events with invited overseas buyers—shows that the natural products industry has now moved beyond introducing local specialties and entered a full-fledged stage of overseas brand competition.

The gut health market has moved beyond simply competing to add more probiotics and is shifting toward reading each individual’s gut environment and designing products accordingly. Companies are differentiating products by combining probiotics with prebiotics, postbiotics, and proprietary strains, making data and formulation design capabilities the new benchmarks. This shift comes as growth in South Korea’s health functional food market has slowed after rapid expansion. As the market matures, generic products are more likely to be trapped in price competition, prompting companies to strengthen efforts to secure repeat purchases and higher value through more sophisticated functional explanations and personalized experiences.

In the field of Korean medicine, there have been simultaneous moves to refine market entry procedures for product development and distribution while drawing stricter lines around insurance coverage. The Ministry of Food and Drug Safety revised the [Regulations on the Approval and Notification of Herbal (Crude Drug) Preparations, etc.] to streamline review materials in a way that reflects the characteristics of herbal preparations... This trend does not indicate a blanket deregulation or expansion of Korean medicine; rather, it suggests a direction of establishing standardized procedures on the industrial side and clarifying standards for the use of public funds on the healthcare coverage side. As a result, companies and institutions gain a more predictable regulatory environment, but practitioners in the field also face growing pressure to provide more detailed clinical evidence and billing appropriateness.